Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Real-World Assessment of DBS Outcomes Using a 16-Contact Device Capable of Multiple Independent Current Control: A Retrospective Outcomes Study
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
108
Here, we report the real-world clinical outcomes associated with the use of DBS systems capable of directionality and Multiple Independent Current Control (MICC) in overall quality of life and the use of medications.
Deep Brain Stimulation (DBS) is an established treatment for motor signs and fluctuations associated with Parkinson’s disease (PD). Retrospective studies can provide a relatively quick and cost-effective means to obtain data regarding various types of patient outcomes when devices are being used per standard-of-care in the real-world clinical setting, thereby contributing to real-world evidence (RWE). Here, we report clinical outcomes associated with the use of DBS systems capable of directionality and Multiple Independent Current Control (MICC). 
This is an international,  multi-center observational study of DBS patient outcomes (NCT03664609) based on retrospective chart review. Patients assessed were implanted with a DBS system (Vercise, Boston Scientific) capable of MICC and/or directionality for use in the treatment of motor symptoms of Parkinson’s disease. Data related to disease state, motor function, and overall quality of life are collected. Additionally, reduction in anti-parkinsonian medications usage is also assessed.
To date, data from 132 patients have been collected (Mean age 65.2 ± 9.4 years, 71.8% male). Of the patient data currently available (n = 53), 77% (n=41) of patients reported a reduction in anti-parkinsonian medications at 12 months post implant. Ninety three percent (54 of 58) of clinicians and 88% (51 of 58) reported improvement in PD symptoms post DBS implant at their last follow up visit. Additional data will be presented.
Reports from this ongoing real-world observational study report an overall improvement in quality of life and reduction in anti-parkinsonian medication following DBS. Outcomes from this study continue to add to the compendium of data examining real-world DBS outcomes in patients with Parkinson’s Disease.
Authors/Disclosures
Corneliu C. Luca, MD (University of Miami)
PRESENTER 		Dr. Luca has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Boston Scientific. Dr. Luca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Signant Health. Dr. Luca has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbott.
Theresa A. Zesiewicz, MD (University of South Florida) Dr. Zesiewicz has received personal compensation for serving as an employee of Medscape. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lexeo. Dr. Zesiewicz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Steminent. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Larimar. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
Lilly Chen (Boston Scientific) Lilly Chen has received personal compensation for serving as an employee of Boston Scientific .
Roshini Jain Roshini Jain has received personal compensation for serving as an employee of Boston Scientific. Roshini Jain has received stock or an ownership interest from Boston Scientific.